ANALYSIS | PRODUCT INNOVATION | sell Nalox in several major markets in
Europe, including Germany, France, Spain and the UK. The launches are scheduled to start during the first half of 2012. Meda paid SKr50 million for European
exclusivity rights, of which SKr21 million was up-front and the rest in milestone payments. This payment, in combination with the rapid growth, helped Moberg Derma turn in a first-time quarterly operating profit in Q3 2011, and in Q4 first net profit, of SKr4.4 million, on sales of Skr56 million in calendar 2011 (reported on 9 February 2012). The goal is to be cash-flow positive and generate an annual operating profit from 2013. In Italy, Moberg Derma partnered in late
2011 with Menarini, which will sell Nalox as YouDerm Emtrix. The company is now also present in Australia, and the ongoing expansion of its coverage means that, within a short time, it has extended its market reach from 25 million people in the Nordic territories to some 1 billion globally. To build its position further, Moberg
Derma uses feedback from its network of distribution partners and brings groups of
dermatologists together. It also works with specialists at the Karolinska Institute in Sweden, where the company was founded, the Sahlgrenska University Hospital, and with German and US dermatologists. Additionally, in the US, its product is being carried by the pharmacy chains CVS, Rite Aid and Walgreens, other than Walmart. Moberg Derma also aims
to educate the market and distributors by ensuring scientific staff are present at meetings, and by engaging with local opinion-formers. For instance, in February 2012 Moberg Derma presented at the New York School of Podiatry, and in March will do so at the American Academy of Dermatologists (AAD) meeting.
Even with growth
products. SMEs have to work hard to be noticed. 'WeÕ re too small for many investors, so we need to get them to
understand the company and how it differs from a biotech or a pharma.'
with fungicidal, keratolytic and emollient properties, MOB-015. In December 2011, Moberg Derma completed the recruitment of 237 patients with onychomycosis to participate in a phase II study. Final results from this phase are expected by the end of 2012. Data analysed by the
company in early February showed, however, that there appeared to be a low probability that the final results from the study will be sufficient for out-licensing the project. Further studies will
Extending the business base The development pipeline includes a second-generation fungal nail product
probably be required before continuing to phase III, the company now believes. 'We will get additional data and seek to identify possible product improvements,' says Mr Wolpert. As to the formulation technology of
MOB-015, it facilitates high concentrations of a fungicidal substance to be transported in and through the nail tissue. In
Visit us at the AMWC 2012 Booth E25
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112